The EU authorizes the drug daraxonrasib for metastatic pancreatic cancer: breakthrough thanks to the tenacity of 36-year-old Jessica Scarpa

The tenacity of Jessica Scarpa, 36 years old from Olginate, has marked a decisive turning point for thousands of cancer patients: Sandra Gallina, Director General for Health and Food Safety of the European Commission, has officially authorized the marketing throughout the European Union and in the European Economic Area of ​​Rasonque, the new oral medicine based on daraxonrasib indicated for metastatic pancreatic cancer. After starting a fundraiser to access the therapy in the United States, where the treatment costs around 40,000 dollars a month, the woman was already receiving free treatment at the Lecco hospital thanks to the intervention of the Lombard Welfare Councilor Guido Bertolaso.

The announcement was made from Brussels by Fratelli d’Italia MEP Lara Magoni, who had urged the commissioners with a specific question and urged the institutions to ensure that the authorization does not remain on paper. Now the matter passes to the Minister of Health Orazio Schillaci to quickly define the price and reimbursement by the National Health Service, while the thirty-six year old looks forward to the fourth birthday of her twins, Thiago and Leone, determined to celebrate it with them in January.

Jessica’s journey after her June 2025 diagnosis and fundraising

It all began for Jessica Scarpa in June 2025 when she was diagnosed with pancreatic cancer, initially treated with surgery and chemotherapy, which then evolved into a metastatic form. To access daraxonrasib, purchased in the United States at a cost of around 40,000 dollars a month, an online fundraiser was started which exceeded 500,000 euros.

The intervention of the Lombardy Region and the direct purchase of the drug in the USA by the Asst of Lecco changed things and allowed her to start the therapy in Lecco already last Thursday without having to leave overseas. At that point the collection was interrupted and a portion began to be returned to donors and another portion to be allocated to scientific research. But his battle reached the European Commission, transforming his personal story into an achievement for all patients.

Clinical data of daraxonrasib: survival almost doubled

The European approval is based on the results of the international phase 3 study conducted on 500 adult patients with metastatic pancreatic adenocarcinoma already treated with at least one previous systemic therapy, in 92% of whom a RAS G12 mutation was present. The medicine developed by Revolution Medicines brought the median overall survival to 12.4 months, compared to 6.7 months recorded with traditional chemotherapy, guaranteeing an average gain of 5.7 months.

Even clearer is the data on progression-free survival, which went from 3.6 months to 7.2 months, an exactly double value. From a pharmacological point of view, the active ingredient belongs to the inhibitors of RAS proteins, responsible for the uncontrolled proliferation of tumor cells: by binding to the cyclophilin A protein, it forms a complex that blocks the activity of RAS, promoting cell death, with manageable side effects such as diarrhea, skin rashes, stomatitis, nausea and vomiting.

An accelerated assessment in less than 150 days

The approval also marks a first on a regulatory level thanks to the EMA’s Cancer Medicines Pathfinder project, which has included the drug among the priority treatments for unmet clinical needs, after having already granted it the European designation of orphan medicinal product on 20 April 2026. Through a phased evaluation procedure started in July 2026, the Committee for Medicinal Products for Human Use (CHMP) progressively examined the dossiers, completing the investigation in less than 150 days, compared to the 210 days of active evaluation and the overall year normally required by ordinary procedures. The drug also falls under the European regulation on Health Technology Assessment (HTA) for joint clinical evaluation, tracing a new speed model for bringing innovative therapies to patients.